potential €6.45-billion offer significantly undervalued the Spanish drugmaker’s prospects and long-term potential.
Grifols said its board would meet later on Tuesday to consider the potential offer, but that, given the valuation, it would not be in a position to recommend that shareholders accept it.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: